Biontech Se Stock Cash Per Share
| 0A3M Stock | USD 119.15 1.45 1.23% |
BioNTech SE fundamentals help investors to digest information that contributes to BioNTech's financial success or failures. It also enables traders to predict the movement of BioNTech Stock. The fundamental analysis module provides a way to measure BioNTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioNTech stock.
BioNTech | Cash Per Share |
BioNTech SE Company Cash Per Share Analysis
BioNTech's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current BioNTech Cash Per Share | 3.75 X |
Most of BioNTech's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNTech SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
BioNTech Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, BioNTech SE has a Cash Per Share of 3.75 times. This is 13.79% lower than that of the Biotechnology sector and 13.39% lower than that of the Health Care industry. The cash per share for all United Kingdom stocks is 25.15% higher than that of the company.
Did you try this?
Run Instant Ratings Now
Instant RatingsDetermine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
BioNTech Fundamentals
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.17 | ||||
| Profit Margin | 0.48 % | ||||
| Operating Margin | 0.64 % | ||||
| Current Valuation | 11.57 B | ||||
| Shares Outstanding | 239.77 M | ||||
| Shares Owned By Insiders | 65.11 % | ||||
| Shares Owned By Institutions | 17.59 % | ||||
| Price To Book | 1.42 X | ||||
| Price To Sales | 3.57 X | ||||
| Revenue | 3.82 B | ||||
| Gross Profit | 16.07 B | ||||
| EBITDA | 5.94 B | ||||
| Net Income | 930.3 M | ||||
| Cash And Equivalents | 914.9 M | ||||
| Cash Per Share | 3.75 X | ||||
| Total Debt | 28.1 M | ||||
| Debt To Equity | 0.05 % | ||||
| Current Ratio | 2.67 X | ||||
| Book Value Per Share | 83.02 X | ||||
| Cash Flow From Operations | 5.37 B | ||||
| Earnings Per Share | 18.00 X | ||||
| Price To Earnings To Growth | 0.05 X | ||||
| Target Price | 219.54 | ||||
| Number Of Employees | 5.5 K | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 32.8 B | ||||
| Total Asset | 23.01 B | ||||
| Retained Earnings | 19.76 B | ||||
| Working Capital | 17.46 B | ||||
| Net Asset | 23.01 B |
About BioNTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNTech SE's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNTech SE based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.